Anand Patel to Myeloproliferative Disorders
This is a "connection" page, showing publications Anand Patel has written about Myeloproliferative Disorders.
Connection Strength
5.716
-
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):484-493.
Score: 0.803
-
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia. Haematologica. 2025 Apr 01; 110(4):828-839.
Score: 0.786
-
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024 07 09; 8(13):3468-3477.
Score: 0.770
-
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55.
Score: 0.697
-
SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):303-309.
Score: 0.696
-
Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
Score: 0.600
-
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
Score: 0.600
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.576
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
Score: 0.188